WilliamT.KoMDFAAD
Dermatology • Scottsdale, AZDermatologic Surgery
President - Arizona Dermatology Group External Partnership Director - Biomarck Pharmaceuticals (2020-2022) Scientific Advisory Board - Biomarck Pharmaceuticals (2012-2021) Researcher - Arizona Research Center Clinical Preceptor - AT Still University Clinical Preceptor Midwestern University
Dr. Ko is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4835 e cactus rd
155
Scottsdale, AZ 85254Phone+1 602-996-2997Fax+1 602-494-0481
Summary
- Board certified Dermatologist with expertise with general dermatology, MOHs surgery, psoriasis, clinical research, infectious diseases, and complex dermatological cases. I launched biologic drugs in Arizona with dermatologists and continue clinical research with psoriasis and atopic dermatitis. I am a clinical preceptor for both Midwestern university and A.T. Still medical schools. The development of new drugs is an interest of mine and I am proud to have been part of several new companies with drug development to positively affect patients suffering with psoriasis, eye diseases, cancer, and hypogonadism.
Education & Training
Cleveland Clinic FoundationResidency, Dermatology, 1994 - 1998
Northeast Ohio Medical UniversityClass of 1994
Certifications & Licensure
AZ State Medical License 1998 - 2026- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- CASTLE CONNELLY'S Top Doctors in Dermatology In the United States Castle Connolly, 2012-2024
- Phoenix Magazine's TOP DOCS 2003-2024
- ARIZONA BUSINESS MAGAZINE'S TOP 100 PHYSICIANS IN ARIZONA OVER ALL SPECIALTIES ARIZONA BUSINESS MAGAZINE, 2023
- Join now to see all
Clinical Trials
- A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis
- Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis Start of enrollment: 2004 Jan 01
- Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis Start of enrollment: 2003 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 12 citationsFluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: equivalent efficacy with a lower concentration and more convenient dosing schedule.Joseph L. Jorizzo, Patrick S Carney, William T Ko, Perry Robins, Susan H Weinkle
Cutis. 2004-12-01 - 22 citationsTreatment options in the management of actinic keratosis.Joseph L. Jorizzo, Patrick S Carney, William T Ko, Perry Robins, Susan H Weinkle
Cutis. 2004-12-01 - 10 citationsMatching patients with therapy.Joseph L. Jorizzo, Patrick S Carney, William T Ko, Perry Robins, Susan H Weinkle
Cutis. 2004-12-01
Press Mentions
The 100 Best Doctors in Arizona for 2024December 15th, 2023
Professional Memberships
- Fellow
- Fellow
Industry Relationships
- speaker, Orthodermatologics
- speaker, Abbvie
- speaker, Regeneron/ Sanofi
- speaker, Celgene
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
